Bladder Cancer and Risk Factors: Data from a Multi-Institutional Long-Term Analysis on Cardiovascular Disease and Cancer Incidence
Authors:
- Biagio BaroneBiagio Barone
- Marco FinatiMFMarco Finati
- Francesco CinelliFCFrancesco Cinelli
- Antonio FanelliAFAntonio Fanelli
- Francesco Del GiudiceFrancesco Del Giudice
- Ettore De BerardinisEBEttore De Berardinis
- Alessandro SciarraASAlessandro Sciarra
- Gianluca RussoGianluca Russo
- Vito ManciniVMVito Mancini
- Nicola D’altiliaNDNicola D’altilia
- Matteo FerroMFMatteo Ferro
- Angelo PorrecaAPAngelo Porreca
Open Access
- 13 March 2023
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (3) , 512
Abstract
Background: Bladder cancer (BCa) is a heterogeneous disease with a variable prognosis and natural history. Cardiovascular disease (CVD), although completely different, has several similarities and possible interactions with cancer. The association between them is still unknown, but common risk factors between the two suggest a shared biology. Materials and Methods: This was a retrospective study that included patients who underwent transurethral resection of bladder tumor at two high-volume institutions. Depending on the presence of a previous history of CVD or not, patients were divided into two groups. Results: A total of 2050 patients were included, and 1638 (81.3%) were diagnosed with bladder cancer. Regarding comorbidities, the most common were hypertension (59.9%), cardiovascular disease (23.4%) and diabetes (22.4%). At univariate analysis, independent risk factors for bladder cancer were age and male sex, while protective factors were cessation of smoking and presence of CVD. All these results, except for ex-smoker status, were confirmed at the multivariate analysis. Another analysis was performed for patients with high-risk bladder cancer and, in this case, the role of CVD was not statistically significant. Conclusions: Our study pointed out a positive association between CVD and BCa incidence; CVD was an independent protective factor for BCa. This effect was not confirmed for high-risk tumors. Several biological and genomics mechanisms clearly contribute to the onset of both diseases, suggesting a possible shared disease pathway and highlighting the complex interplay of cancer and CVD. CVD treatment can involve different drugs with a possible effect on cancer incidence, but, to date, findings are still inconclusive.Keywords
This publication has 33 references indexed in Scilit:
- Nonsteroidal anti‐inflammatory drugs and other analgesic use and bladder cancer in northern New EnglandInternational Journal of Cancer, 2012
- Cardiovascular Medications and Risk of CancerThe American Journal of Cardiology, 2011
- T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomyInternational Urology and Nephrology, 2011
- Nonsteroidal Antiinflammatory Drugs and Bladder Cancer: A Pooled AnalysisAmerican Journal of Epidemiology, 2011
- Hypertension, diuretics and antihypertensives in relation to bladder cancerCarcinogenesis, 2010
- Immunity, Inflammation, and CancerCell, 2010
- Tumor-like lesions of the urinary bladderLaboratory Investigation, 2009
- Screening statins for possible carcinogenic risk: up to 9 years of follow‐up of 361 859 recipientsPharmacoepidemiology and Drug Safety, 2007
- Bladder cancer: Epidemiology, staging and grading, and diagnosisUrology, 2005
- Accumulation of Nuclear p53 and Tumor Progression in Bladder CancerNew England Journal of Medicine, 1994